Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The primary objective of the study is to compare the overall response rate (inclusive of complete response, partial response and hematologic improvement) per IWG 2006 criteria in patients with higher risk MDS treated with azacitidine with or without deferasirox achieved over the course of one year. Hematologic improvement must be maintained for at least 8 weeks.
Epistemonikos ID: 5a33a49db61320aec4cee7a1b2fd243ae7b4c8f5
First added on: May 11, 2024